Multicenter phase II study of lapatinib in patients with brain metastases from HER2-positive breast cancer. - Wikidata - wikimedia - TriplyDB

Multicenter phase II study of lapatinib in patients with brain metastases from HER2-positive breast cancer.

Multicenter phase II study of lapatinib in patients with brain metastases from HER2-positive breast cancer.

http://www.wikidata.org/entity/Q46116627

about

Brain metastasis in human epidermal growth factor receptor 2-positive breast cancer: from biology to treatment National consensus in China on diagnosis and treatment of patients with advanced breast cancer Breast cancer brain metastases: the last frontier Human epidermal growth factor receptor 2 positive (HER2+) metastatic breast cancer: how the latest results are improving therapeutic options Emerging treatment options for the management of brain metastases in patients with HER2-positive metastatic breast cancer Molecular interactions in the development of brain metastases Potential of afatinib in the treatment of patients with HER2-positive breast cancer PI3K pathway inhibitors for the treatment of brain metastases with a focus on HER2+ breast cancer Targeted Therapies for Brain Metastases from Breast Cancer Breast Cancer Brain Metastases: Clonal Evolution in Clinical Context.Systemic therapy of brain metastases: non-small cell lung cancer, breast cancer, and melanoma.Ultrasound-mediated blood-brain/blood-tumor barrier disruption improves outcomes with trastuzumab in a breast cancer brain metastasis model.Phase II trial of lapatinib in adult and pediatric patients with neurofibromatosis type 2 and progressive vestibular schwannomas.A pilot study of bevacizumab combined with etoposide and cisplatin in breast cancer patients with leptomeningeal carcinomatosis.DEGRO Practical Guidelines for palliative radiotherapy of breast cancer patients: brain metastases and leptomeningeal carcinomatosis.Lapatinib plus capecitabine in treating HER2-positive advanced breast cancer: efficacy, safety, and biomarker results from Chinese patients.Carmustine and methotrexate in combination after whole brain radiation therapy in breast cancer patients presenting with brain metastases: a retrospective study.Incidence of central nervous system metastases in patients with HER2-positive metastatic breast cancer treated with pertuzumab, trastuzumab, and docetaxel: results from the randomized phase III study CLEOPATRA.Current approaches to the treatment of metastatic brain tumours.Treatment of HER2-positive metastatic breast cancer with lapatinib and capecitabine in the lapatinib expanded access programme, including efficacy in brain metastases--the UK experience.Progress in the biological understanding and management of breast cancer-associated central nervous system metastases.Translational research in brain metastasis is identifying molecular pathways that may lead to the development of new therapeutic strategies.Trastuzumab uptake and its relation to efficacy in an animal model of HER2-positive breast cancer brain metastasis Multifactorial central nervous system recurrence susceptibility in patients with HER2-positive breast cancer: epidemiological and clinical data from a population-based cancer registry study.Protein pathway activation mapping of brain metastasis from lung and breast cancers reveals organ type specific drug target activation TBCRC 018: phase II study of iniparib in combination with irinotecan to treat progressive triple negative breast cancer brain metastases.Lapatinib for the treatment of breast cancer in the People's Republic of China.Brain metastases from breast cancer: prognostic significance of HER-2 overexpression, effect of trastuzumab and cause of death A nomogram for predicting distant brain failure in patients treated with gamma knife stereotactic radiosurgery without whole brain radiotherapy.Activity of T-DM1 in HER-2 positive central nervous system breast cancer metastases The Role of Targeted Agents in the Treatment of Metastatic Breast Cancer.Systemic Therapy for Women with ErbB2-Positive Breast Cancer: New Options, New Challenges.Significance of Tyrosine Kinase Inhibitors in the Treatment of Metastatic Breast Cancer.Brain Metastases of Her2-Positive Breast Cancer: A Case of 34 Months' Remission with Lapatinib plus Capecitabine.Phase I trial of lapatinib in children with refractory CNS malignancies: a Pediatric Brain Tumor Consortium study.Management of ErbB2-positive breast cancer: insights from preclinical and clinical studies with lapatinib.Therapeutic Considerations in Treating HER2-Positive Metastatic Breast Cancer Relationship between HER-2 overexpression and brain metastasis in esophageal cancer patients.Clinical outcomes of HER2-positive metastatic breast cancer patients with brain metastasis treated with lapatinib and capecitabine: an open-label expanded access study in Korea.The molecular genomics of metastatic brain tumours.

P2860

Q26751008-F87DB48B-A1F3-4F51-86D5-FA276E976719 Q26775621-BFF5BC34-E19D-487C-94E2-5E72B43F551F Q26775663-4E79A017-5BEC-4950-9D6C-712691F9E6BA Q26777681-903ADDBA-E4EA-45AB-AC39-37D892009DCD Q26824799-14C23B30-85D2-4EBE-9BA2-1F9801B66598 Q26865865-AD411989-D378-4043-A98E-B8FEFBD0A542 Q26999050-84B44815-B09C-46FC-BAE9-3E754A32B42C Q27006181-D1E0F140-0DAC-4C93-A498-BDFC8DC9987D Q28068154-AA51992F-B55E-4B22-810C-EFF7933ABDC8 Q30238959-69DB19C3-6D6D-48BE-9FB0-0CD57B05F93C Q30239901-81218F84-48D1-400D-B86B-2F26D005756B Q30447321-4ECB21EA-4CB5-43CD-A911-48C22FAAE443 Q30450038-0AC2E000-28D0-4E51-8528-971F3787C7F6 Q30641737-BDE2651E-661D-4BC8-99DA-39FE2B6E8426 Q33529158-46313378-2090-4598-BA71-E9C881B8B8FA Q33579653-03CBFF6F-C5E3-4DCF-9FE5-F35AA6F53E2B Q33595274-B6E6B671-9577-41F2-BBBE-2DC89AF67701 Q33683140-F7F5528F-E396-45A7-8573-AAE248E8D323 Q33696559-8AAA7C63-DB86-4F10-8DB7-16354F513F7E Q33747400-4C20ADE9-A277-46D3-9F99-7A5AE8F0018B Q33777436-748976B4-053E-4A19-96D6-D1236C584BA9 Q33805406-60B25E81-ED87-43D8-A91B-2212E489F415 Q33867316-53D44ECE-7D9A-45FA-8BD3-FCE7F815CA99 Q33878643-BAC71B2F-3550-402F-98CD-A8E95B294EB4 Q33901255-00E08A05-78E7-4EA2-BCBE-2ECC5D8C5253 Q33954557-B6C86D2F-B8F9-47FE-B68D-5848B8CB5ADE Q34016491-5D8441B5-CB34-4FB6-AF0D-0BCFBA28CAC7 Q34022312-F97389D6-FC56-4BAC-AD04-12D4FEF8C14E Q34061998-0FBFDB68-8ACF-4E65-A2B0-41FF703345F9 Q34071514-D974BA23-1240-475D-B07D-97405CBD72D4 Q34096063-BA6B9DC7-3660-4D9C-92BE-1F521ECF9197 Q34096218-FA1F6B62-1A3B-422F-9342-637C3D9E672C Q34140058-29BACA02-6CFB-4DC0-B47B-070AAE3716EB Q34181224-BD445ABD-AB87-4166-A9EB-F4FDDFDC44FA Q34193975-877ABFAB-A4E3-4EE2-8A20-1FAC4B9CB901 Q34241118-A56CCA47-ABED-4C84-8469-572105AF5882 Q34268618-BA81B848-677E-49F2-8E63-5F2D759E4834 Q34285753-6C24BEE9-B6DC-491A-B62F-2C9720E22BC8 Q34354224-A17E9CD1-A78C-479F-9F6A-693DFA36F3A7 Q34499855-80871C15-6F08-455F-BDAC-778B20C02A9A

P2860

Multicenter phase II study of lapatinib in patients with brain metastases from HER2-positive breast cancer.

http://www.wikidata.org/entity/Q46116627

description

2009 nî lūn-bûn

@nan

2009年の論文

@ja

2009年学术文章

@wuu

2009年学术文章

@zh

2009年学术文章

@zh-cn

2009年学术文章

@zh-hans

2009年学术文章

@zh-my

2009年学术文章

@zh-sg

2009年學術文章

@yue

2009年學術文章

@zh-hant

name

Multicenter phase II study of ...... m HER2-positive breast cancer.

@en

Multicenter phase II study of ...... m HER2-positive breast cancer.

@nl

type

label

Multicenter phase II study of ...... m HER2-positive breast cancer.

@en

Multicenter phase II study of ...... m HER2-positive breast cancer.

@nl

prefLabel

Multicenter phase II study of ...... m HER2-positive breast cancer.

@en

Multicenter phase II study of ...... m HER2-positive breast cancer.

@nl

P1433

Q46116627-8D2B5274-9642-4C30-8996-7AD21767F2F4

P1476

Q46116627-EB2F68C5-DDEB-4842-A153-591DCEB92815

P2093

Q46116627-01CED384-280A-48CF-9DA9-8A7621AF6875

Q46116627-08DACC00-496B-4207-A6AB-D75994EF0617

Q46116627-0E263528-DF77-4704-92E1-34DBB6DA73F6

Q46116627-19060F6F-4312-454C-8EF6-E983115BB3DA

Q46116627-1BEB3270-DFEC-439A-8071-CE9C38D9E1AD

Q46116627-239967D6-67AA-43C0-BF42-65B8982BD94C

Q46116627-2DBCF372-CE4E-4B46-B2E6-B03BE431EDC9

Q46116627-427294C0-F46A-4C3F-8ABE-F0E7544DF6D8

Q46116627-47C9BBBA-61BF-4327-A299-5F7AC0F4AD81

Q46116627-6861A07F-1B3C-4B4D-AA88-2BD86DCE75B7

P304

Q46116627-34D7E5B1-667C-4ABA-9021-0D97EC40EB5A

P31

Q46116627-0A4FFCBB-DCCE-4C3E-9387-3E263738699D

P356

Q46116627-ADFB1C10-3011-47D6-A1B3-8F11B43DF062

P407

Q46116627-F5C30C60-A2C5-4B09-B5FA-03AE96A6A3D0

P433

Q46116627-1953F9C9-1D17-4F5C-9E58-4A2F8D4D7111

P478

Q46116627-8F1D4CA8-8003-43D6-B8CC-4AF82C5DCBCC

P50

Q46116627-4BA6C368-6E94-4B37-A4E1-4C0A4598D1E6

Q46116627-99D009E1-993A-4D74-BC66-919498558C79

Q46116627-A142CF63-C9EF-4F9D-A265-983A138E5403

Q46116627-A9B67CBC-588C-4A27-A6B4-62DAAC62936F

P577

Q46116627-CB398DAE-B746-4B30-AD72-4E7272EE6D08

P698

Q46116627-8FDD4700-09C2-4D86-B8BB-FD1BC555C92B

P356

1078-0432.CCR-08-1080

P1433

Clinical Cancer Research

P1476

Multicenter phase II study of ...... m HER2-positive breast cancer.

@en

P2093

Adam Brufsky

http://www.w3.org/2001/XMLSchema#string

Bernie Dharan

http://www.w3.org/2001/XMLSchema#string

Christos Christodoulou

http://www.w3.org/2001/XMLSchema#string

Cristina Oliva

http://www.w3.org/2001/XMLSchema#string

Debasish Roychowdhury

http://www.w3.org/2001/XMLSchema#string

Denise Yardley

http://www.w3.org/2001/XMLSchema#string

Denise Zembryki

http://www.w3.org/2001/XMLSchema#string

Devchand Paul

http://www.w3.org/2001/XMLSchema#string

Dominique Lossignol

http://www.w3.org/2001/XMLSchema#string

Eric P Winer

http://www.w3.org/2001/XMLSchema#string

P304

1452-1459

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1158/1078-0432.CCR-08-1080

http://www.w3.org/2001/XMLSchema#string

P407

P433

4

http://www.w3.org/2001/XMLSchema#string

P478

15

http://www.w3.org/2001/XMLSchema#string

P50

Andrew M. Wardley

P577

2009-02-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

19228746

http://www.w3.org/2001/XMLSchema#string